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Design and synthesis of triazole-based
peptidomimetics of a PSD-95 PDZ domain
inhibitor†‡
Anders Bach,* Thomas B. Pedersen and Kristian Strømgaard
PSD-95 PDZ domains are biologically important and promising drug targets. Here, we discover a triazole-
based peptidomimetic, 10, by ‘click chemistry’. Compound 10 inhibits the PDZ2/GluN2B interaction with
affinity similar to tripeptide SAV and better than current small-molecules. Thus, 10 represents a new class
of PSD-95 PDZ inhibitors.
1. Introduction
Postsynaptic density protein-95 (PSD-95) is a scaffolding pro-
tein found in neuronal synapses.1 PSD-95 contains three post-
synaptic density protein-95/disks-large/zonula occludens-1
(PDZ) domains, which interact with the N-methyl-D-aspartate
(NMDA) receptor and signalling proteins such as neuronal
nitric oxide synthase (nNOS).2 Compounds targeting PDZ1
and PDZ2 of PSD-95 have shown promising effects in animal
models of ischemic stroke,3–5 pain6–8 and neurodegenerative
diseases,9 as they can disconnect disease-related excessive
NMDA receptor activity from harmful down-stream mecha-
nisms.3,10 PSD-95 is particularly promising as a drug target in
relation to ischemic stroke, and peptide-based inhibitors are
being pursued as drug candidates in preclinical and clinical
trials.4,11
PDZ domains are highly abundant in the human prote-
ome and are often found in scaffolding proteins where they
mediate protein–protein interactions and form signalling net-
works of key importance to cellular biology.12,13 In the canon-
ical binding mode PDZ domains bind the C-terminal peptide
part (4–7 amino acids) of its interaction partner
(Fig. 1A and B). The PDZ binding pocket is created by the βB
strand and αB helix of the PDZ domain and is narrow and
shallow and thus well suited to recognize peptides.14–16 A
small hydrophobic sub-pocket binds the side chain of the
C-terminal amino acid (position P0, typically a Val, Leu or Ile)
and serves as an anchor point for the interaction with pep-
tide. The C-terminal carboxylic acid of the peptide ligand is
crucial for binding17 and is accommodated by the conserved
PDZ ‘GLGF’ loop.18 Peptides binding to PDZ domains form
an anti-parallel β-sheet with the PDZ βB strand via amide
backbone hydrogen bonds.14,18,19 Structure–activity relation-
ship (SAR) investigations of both peptide and protein back-
bone have revealed that not all amide atoms of the peptide
engage directly with the PDZ domain. Especially, the P−1
amino acid does not interact with PDZ, but seem to act more
as a spacer that ensures the right positioning of the essential
P0 and P−2 residues (Fig. 1A and B).18–20
Truncation studies of peptide ligands targeting PSD-95
have shown that pentapeptides display affinities similar to
longer peptides, while tetra- and tripeptides show a stepwise
reduction in affinity.15 pentapeptides have subsequently been
derivatized into dimeric inhibitors with nanomolar po-
tency.4,21 Likewise, the affinity of tetrapeptides has been
increased about 20-fold by N-alkylations and stability can be
enhanced by replacing amides with thioamides.15,20 Also,
cyclization and expansion of the P−1 side chain of
hexapeptides have led to peptidomimetic structures with
increased affinities.22,23
Developing small-molecules targeting PDZ domains have
shown to be difficult. Only few small-molecule inhibitors
have been reported and affinities are in the low micromolar
range in best cases.13 Until recently, no small-molecule
PSD-95 PDZ inhibitors existed. However, Vogrig et al.
reported a series of indole-based compounds (Fig. 1C) able
to interact with PSD-95 PDZ domains (1H–15N hetero-
nuclear single-quantum coherence, HSQC, NMR), inhibit the
PSD-95-PDZ/5-HT2A receptor interaction (pull-down) and
relieve pain in hyperalgesic rats.24
Herein, we pursue a peptidomimetic strategy introducing
a rigid scaffold into a short PSD-95 peptide ligand with the
potential of improving affinity, selectivity, and stability and
provide novel chemotypes targeting PSD-95. We used the
tripeptide Thr-Ala-Val (TAV) as starting point (Fig. 1A–C),
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which binds PDZ1 and PDZ2 with medium affinity (PDZ2:
Ki ∼ 40 μM). TAV was identified from a peptide SAR study
of the GluN2B C-terminal revealing that P0 Val is essential
for affinity, P−1 Asp could be replaced with Ala, and Thr in-
stead of Ser in P−2 leads to increased affinity.15 As TAV is
small and reasonably potent it is an attractive starting point
for converting peptides into more small-molecule-like com-
pounds. Here, we prepared azide and alkyne analogues of
the corresponding amino acids and dipeptides of TAV,
which then served as building blocks for subsequent
copperĲI)-catalyzed azide–alkyne cycloaddition (CuAAC) reac-
tions thereby producing a series of 1,2,3-triazole containing
analogues of TAV.25,26 Triazole resembles amide in planar-
ity, size and electronic properties and has previously been
used as an amide bioisoster resulting in potent and prote-
ase stable compounds.27–30 Thus, here we systematically in-
vestigated triazole as a potential bioisoster in PSD-95 PDZ
domain peptide inhibitors and the possibility to rigidify the
peptide backbone by implementing this small and aromatic
ring. This strategy led to the identification of a new triazole-
containing peptidomimetic against the PDZ2 domain of
PSD-95.
2. Results and discussion
2.1. Design and synthesis
In the design process we first fragmentized TAV into the
amino acid and dipeptide moieties (Thr, Thr-Ala, Ala-Val and
Val) and replaced the resulting amines with azide groups and
carbonyls with methyl azides to generate the four azide build-
ing blocks (1–4, Fig. 2). Likewise, carbonyls of peptide frag-
ments were replaced with acetylene to get alkyne 5 and 6. Ad-
ditionally, alkynes 7–8 were made where the acetylene
replaces the central part of P−1 Ala and the important P0 and
P−2 (Val and Thr) amino acids were preserved (Fig. 2). For 8,
an alcohol group needed to replace the intended carbonyl in
order to provide a water-stable building block. For both 7
and 8 it was envisioned that the carbonyl/alcohol could facili-
tate hydrogen bond interactions with the PDZ backbone. Af-
ter preparing the building blocks, the strategy was to react
Fig. 1 (A) pentapeptide IESDV (green), derived from the GluN2B sequence, and tripeptide TAV (magenta) docked into PSD-95 PDZ2. (B) Schematic
2D plot of TAV–PDZ2 interactions. (C) Reference compounds used herein: tripeptide TAV and indole-based small-molecules.
Fig. 2 Azides 1–4 and alkynes 5–8 are combined into triazole-based peptidomimetic structures 9–18 all bearing a C-terminal Val and carboxylic
acid.
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the four azides (1–4) with the four alkynes (5–8) applying the
CuAAC reaction so that the corresponding triazole structures
(9–18) contained at least one Val and carboxylic acid group
intended to bind into the PDZ domain P0 pocket (Fig. 2). This
systematic strategy allows for a thorough investigation of the
idea of introducing a rigid scaffold into the TAV backbone.
The synthesis of azides (1–4) and alkynes (5–8) were car-
ried out in satisfactorily yields generally following standard
procedures (Schemes 1 and 2). Azide 1 was synthesized in
one step from L-valine in a diazo transfer reaction mediated
by freshly prepared triflyl azide according to literature proce-
dure.31,32 To generate azide 2, 19 (prepared by reduction of
Boc- and tert-butyl protected L-threonine33) was mesylated on
the alcohol group to provide intermediate 20 followed by a
nucleophilic substitution reaction by treatment of sodium
azide34 to get 21. Azide 2 was then obtained under mild
deprotection conditions applying HCl in dioxane (Scheme 1).
Azide 3 was synthesized by a solid-phase procedure starting
from a Wang resin preloaded with Fmoc-protected L-valine
(22). After deprotecting the Fmoc, (S)-2-azidopropanoic acid31
was coupled to the free valine amine to get resin-bound inter-
mediate 23. The desired azide 3 was obtained by cleaving the
resin under standard conditions with trifluoroacetic acid
(TFA) (Scheme 1). Azide 4 was synthesized by coupling 24
(ref. 35) with Fmoc- and tert-butyl protected L-threonine using
HBTU followed by deprotection under mild acidic conditions
(Scheme 1).
Next, alkyne building blocks (5–8) were synthesized. To
prepare 5, the Boc- and tert-butyl protected L-threonine was
first converted to the corresponding aldehyde Boc-ThrĲtBu)-
CHO (25).33 This aldehyde was then reacted with freshly in
situ prepared Bestmann–Ohira reagent (dimethyl diazo-2-
oxopropylphosphonate),36 and the resulting intermediate al-
kyne 26 was readily deprotected in iodotrimethylsilane to
generate 5 (Scheme 2).37 Likewise, the synthesis of alkyne 6
started with aldehyde 27 (Boc-Ala-CHO38) and reaction with
the Bestmann–Ohira reagent to generate 28 (Scheme 2). After
deprotecting the Boc this intermediate was coupled with Boc-
ThrĲtBu)-OH followed by another deprotection to facilitate al-
kyne 6. Alkyne 7 was generated by a solid-phase strategy where
propiolic acid was coupled to resin-bound L-valine using
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)25,39 to
get intermediate 30 followed by cleavage from the resin
(Scheme 2). Alkyne 8 was synthesized by a Grignard reaction
where ethynylmagnesium chloride was added to the carbonyl
of aldehyde 25 followed by deprotection with TFA (Scheme 2).
The triazole-based peptidomimetic structures 9–18 were
then synthesized by standard CuAAC reaction conditions
using a 1 : 1 ratio of alkyne and azide, 0.4 eq. CuSO4 and 2
eq. sodium L-ascorbate in water/tert-butanol at room temper-
ature (ESI‡). For 11–18, the reactions completed within 30
minutes and compounds were obtained in reasonably to fine
yields (>30%) after HPLC purification. Triazoles 9 and 10,
both based on alkyne 5, needed modified conditions to give
satisfactorily yields (66–67%). For 9, heating to 55 °C for 18
hours was applied, while for 10, acetonitrile (20%) replaced
tert-butanol, more sodium L-ascorbate (6 eq.) was added to-
gether with DIPEA and reaction time was prolonged to 65
hours at room temperature. Solutions of all tested com-
pounds were prepared in deuterated PBS buffer and concen-
trations accurately determined by qNMR prior to assay tests.
2.2. Biological evaluation
Triazole-based compounds 9–18 were tested in a fluorescence
polarization (FP) assay in a heterologous competition
mode.15,20,21 Increasing concentrations of test substance were
added to a fixed concentration of PDZ protein and fluores-
cent peptide probes, which were prepared by Cy5-labeling
11-mer peptides corresponding to the C-termini of the
GluN2B subunit of NMDA receptors or CRIPT.15 We first
tested 9–18 against PDZ2 of PSD-95 together with the con-
trol tripeptides TAV and the weaker binding tripeptide
Scheme 1 Synthesis of azides 1–4. Reagents and conditions: (a) Tf2O,
NaN3, H2O, CH2Cl2, 0 °C, 2 h; (b) CuSO4, K2CO3, H2O, CH3OH, CH2Cl2,
rt, overnight; (c) MsCl, Et3N, CH2Cl2, 0 °C to rt, 4 h; (d) NaN3, DMF, 50
°C, 18 h; (e) 4 M HCl in dioxan, rt, 1.5 h; (f) 20% piperidine in DMF; (g)
(S)-2-azidopropanoic acid, HATU, HOAt, collidine, DMF, rt, 3 h; (h) TFA/
tips/H2O (90/5/5), rt, 2 h; (i) Boc-ThrĲtBu)-OH, HBTU, DIPEA, DMF, rt,
12 h; (j) 4 M HCl in dioxan, rt, 1.5 h.
Scheme 2 Synthesis of alkynes 5–8. Reagents and conditions: (a)
p-TsN3, K2CO3, CH3CN, rt, 2 h; (b) Boc-ThrĲtBu)-CHO (25), CH3OH, rt,
overnight; (c) (CH3)3Sil, CH2Cl2, rt, 10 min; (d) Boc-Ala-CHO (27),
CH3OH, rt, overnight; (e) TFA :CH2Cl2 (1 : 1), 0 °C; (f) Boc-ThrĲtBu)-
OH, HATU, DIPEA, DMF, rt, 3 h; (g) 20% piperidine in DMF; (h)
propiolic acid, EEDQ, DMF, rt, 2 h; (i) TFA :CH2Cl2 : H2O (47.5 : 47.5 : 5),
rt, 2 h; (j) ethynylmagnesium chloride, THF, 0 °C, 1 h.
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SAV.15 To compare the triazole compounds with current
leading small-molecule PSD-95 PDZ inhibitors we synthe-
sized Indole 1 and 2 (Fig. 1C) according to literature24 and
tested them in the FP assay.
Among 9–18, compound 10 showed robust inhibition of
the PDZ2/probe interaction with a Ki of 289 μM (Fig. 3). This
affinity is ∼8-fold lower than the TAV tripeptide (Ki = 38 μM)
from which it was designed, but within the same affinity-
range as SAV (Ki = 229 μM). Triazoles 11 and 13 showed some
sign of inhibition (Fig. 3), but affinities were too low to reli-
ably determine the Ki values. Surprisingly, Indole 1 only dem-
onstrated marginal inhibitory activity towards PDZ2, and a Ki
value could not be determined due to a high bottom pla-
teau. Indole 2 was found more potent and gave a credible
inhibition curve and a Ki value of 530 μM towards PDZ2
(Fig. 3).
Next, we tested the active triazole 10 and reference com-
pounds towards PDZ1 and PDZ3 of PSD-95 by FP in a similar
way as for PDZ2. From previous studies it is known that
PDZ1 recognizes the same peptide sequences as PDZ2 al-
though generally with a lower affinity than PDZ2; while the
selectivity profile for PDZ3 is very different from PDZ1 and
PDZ2.15,16 This was reflected in our results, as TAV and SAV
demonstrated higher Ki values towards PDZ1 (74 and 480
μM, respectively) than for PDZ2. For 10 and Indole 1 and 2
some inhibitory activity towards PDZ1 is observed, but their
weaker affinities prevented Ki determination (estimated Ki >
1 mM). For PDZ3 we observed no activity for 10 or the two in-
doles (data not shown).
Overall, these FP data demonstrate that the novel triazole-
based peptidomimetic structure 10 binds PDZ2 of PSD-95
with Ki value of 289 μM and can fully displace the PDZ2/
probe interaction. The affinity to PDZ1 was much weaker (Ki
> 500 μM) and no activity to PDZ3 was observed. Compared
to tripeptides, 10 is equipotent to SAV and 8-fold weaker than
TAV. On the other hand, 10 is several fold more potent than
Indole 1 and about 2-fold more potent than Indole 2. Vogrig
et al.24 demonstrated that Indole 1 inhibits the PSD-95-PDZ1/
5-HT2A interaction with an IC50 of 190 μM in an in vitro pull-
down assay. Indole 2 was not tested in this assay, as it was es-
timated to be a weak binder based on 1H–15N HSQC NMR.
Also, Indole 1 showed analgesic effects in a rat neuropathic
pain model. However, based on our FP data these reported
pharmacological effects might be mediated by other func-
tions than a specific inhibition of PSD-95 PDZ domains.
In order to exclude any unconventional mechanism or
artefactual events of the novel triazole compound we tested
10 by isothermal titration calorimetry (ITC). The ligands, TAV
and 10, were titrated into PDZ2 under low c value conditions.
The c value corresponds to the ratio of the receptor concen-
tration and the dissociation constant and should normally be
10–100 to get high-quality data.40,41 However, for weak inter-
actions this is not practical obtainable and instead experi-
ments are run at low c values (often <1).41 In this alternative
setup it is important that ligand concentration is several fold
higher than protein concentration and that the concentration
of ligand and receptor are precisely known (as stoichiometry
information is lost). When properly designed the integrated
heats form a hyperbolic graph from which the affinity can be
reliable extracted. TAV titrated into PDZ2 resulted in substan-
tial signal, and when integrated heats were fitted to a one-
site binding model Kd was determined to 101 μM (Fig. 4A).
For 10, the measured heats were smaller but still resulted
in a typical and reliable low c value thermogram and Kd
of 598 μM (Fig. 4B). The relative affinities between TAV
and 10 agree very well for FP and ITC, although the Kd
values suggested by ITC were 2–2.5 fold higher than the
FP Ki values. However, this is considered an acceptable
margin considering the low affinities and the concomitant
experimental challenges.41 Overall, the ITC measurements
confirm the FP data and corroborate that 10 binds specifi-
cally to the PDZ2 binding pocket strongly enough to pro-
duce measurable heat in ITC and displace a peptide probe
in FP.
Fig. 3 FP assay: triazoles and reference compounds tested for affinity to PDZ1 and PDZ2 of PSD-95. Cy5-GluN2B is used as probe at 50 nM;
[PDZ2] = 3.75 μM; [PDZ1] = 15 μM. For PDZ2, the following Ki values were determined: 38 ± 9 μM (TAV), 229 ± 15 μM (SAV), 530 ± 96 μM (Indole 2)
and 289 ± 41 μM (10). Ki values for Indole 1, 11 and 13 are >500 μM. For PDZ1, the following Ki values were determined: 74 ± 8 μM (TAV) and 480
± 160 μM (SAV). Error bars indicate SEM based on three individual measurements.
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2.3. Computational evaluation
In order to explore how 10 could interact with PSD-95 PDZ2
we performed computational docking studies using Glide
and a homology model of PDZ2 based on the crystal structure
of PDZ3 in complex with the CRIPT peptide (1BE9),14 as pre-
viously described.15,20,21 When docking penta- and tetra-
peptides into this model these are positioned in the same
conformation as CRIPT in PDZ3 (see Fig. 1) and with an ex-
cellent agreement among the highest ranking docking poses.
For TAV the suggested conformations also align very well
with experimentally determined peptide-PDZ structures, e.g.
Val is positioned in the P0 pocket and backbone interactions
to PDZ are apparent (Fig. 1 and 5). The N-terminal amino
acid, Thr in TAV, shows a higher degree of conformational
variation among the poses, but most conformations suggest
that Thr's hydroxyl group interacts with the β-strand (βB) of
PDZ while the N-terminal amine engages with His225 on the
α-helix (B) as illustrated in Fig. 1 and 5. Docking poses of 10
suggest a binding mode very similar to TAV (Fig. 5). The P0
Val side chain binds in the hydrophobic P0 pocket of PDZ
and the carboxylic acid of 10 interacts with the GLGF loop in
all top 10 poses. Additionally, both 10 and TAV donate their
P0 amide hydrogen to the PDZ backbone. Interestingly, in the
top ranking pose of 10 (Fig. 5), the N3 triazole nitrogen ac-
cepts a hydrogen atom from a PDZ backbone amide bond
similar to the carbonyl group of TAV's P−2 amide illustrating
the amide isosteric properties of triazole. Also, the top pose
of 10 suggests that the P−2 Thr-residue binds PDZ in the
same way as seen for TAV (Fig. 5). However, generally the
poses of 10 agree less well in the P−2 position compared to
TAV, and for example other poses of 10 suggest that its
amine does not interact with PDZ2 at all. Perhaps this varia-
tion in the P−2 region reflects less tight interactions in that
part of the molecule and could perhaps explain why TAV is
more potent than 10. Overall, this computational analysis
illustrates that 10 possesses suitable proportions and
electronic properties allowing it to fit into the PDZ pocket,
and that compound 10 is likely to bind PDZ2 in an similar
mode as the tripeptide TAV.
3. Conclusions
In this study we have pursued a peptidomimetic strategy
where we rigidify the original peptide backbone by introduc-
ing a small triazole group. The feasibility of the CuAAC reac-
tion is exploited to make several close analogues in order to
provide a thorough investigation of the strategy. The short
tripeptide TAV was used as starting point for the design of
triazole-based compounds. Azide and alkyne building blocks
1–8 were synthesized in satisfactorily yields and so were the
corresponding triazole-based peptidomimetic structures
9–18. Compound 10 fully inhibited the PDZ2/peptide probe
interaction with a Ki value of 289 μM. This affinity is lower
than for TAV, but similar to the corresponding SAV tripeptide
and two to several fold better than seen for the recently pub-
lished indole-based small-molecule PSD-95 PDZ inhibitors
(Indole 1–2). ITC studies of 10 show that its interaction with
PDZ2 produces heat and gives a thermogram typical for a
true, but low-affinity, binder. Finally, computational docking
studies suggest that 10 binds PDZ2 in a binding mode very
similar to TAV.
This study illustrates the challenges of generating non-
peptide based PDZ inhibitors with reasonable potencies.
When deviating from the peptide structure ligand-affinity is
often lost, and as seen for the triazole-series even subtle
changes dramatically affect affinity. Also, the affinities of
reported indole small-molecules were found to be low in our
hands. Still, based on our ‘click chemistry’ strategy we dis-
covered compound 10, which represents a novel class of PSD-
95 PDZ inhibitors. It demonstrated reliable inhibitory activity
Fig. 4 Representative ITC data for TAV titrated into 50 μM PDZ2 (A)
and 10 titrated into 35 μM PDZ2 (B). The syringe was loaded with 2305
μM TAV or 5140 μM 10. Results for TAV/PDZ2: Kd = 101 ± 19 μM; ΔH =
−15.0 ± 0.99 kcal mol−1, −TΔS = 9.48 ± 1.1 kcal mol−1. Results for 10/
PDZ2: Kd = 598 ± 136 μM; ΔH = −11.8 ± 3.1 kcal mol−1, −TΔS = 7.42 ±
3.2 kcal mol−1. All values are average ± SD based on three experiments.
Fig. 5 Compound 10 (green) and TAV (magenta) docked into PSD-95
PDZ2. The highest ranking poses are shown.
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in our well-established FP and ITC assays and could inspire
future efforts in the field of PDZ domain medicinal
chemistry.
Notes and references
1 M. Sheng and C. C. Hoogenraad, Annu. Rev. Biochem.,
2007, 76, 823.
2 K. S. Christopherson, B. J. Hillier, W. A. Lim and D. S. Bredt,
J. Biol. Chem., 1999, 274, 27467.
3 M. Aarts, Y. Liu, L. Liu, S. Besshoh, M. Arundine, J. W. Gurd,
Y. T. Wang, M. W. Salter and M. Tymianski, Science,
2002, 298, 846.
4 A. Bach, B. H. Clausen, M. Møller, B. Vestergaard, C. N. Chi,
A. Round, P. L. Sørensen, K. B. Nissen, J. S. Kastrup, M.
Gajhede, P. Jemth, A. S. Kristensen, P. Lundström, K. L.
Lambertsen and K. Strømgaard, Proc. Natl. Acad. Sci. U. S.
A., 2012, 109, 3317.
5 D. J. Cook, L. Teves and M. Tymianski, Nature, 2012, 483,
213.
6 F. Tao, Q. Su and R. A. Johns, Mol. Ther., 2008, 16, 1776.
7 B. W. LeBlanc, M. Iwata, A. P. Mallon, C. N. Rupasinghe,
D. J. Goebel, J. Marshall, M. R. Spaller and C. Y. Saab,
Neuroscience, 2010, 167, 490.
8 R. D'Mello, F. Marchand, S. Pezet, S. B. McMahon and A. H.
Dickenson, Mol. Ther., 2011, 19, 1780.
9 L. M. Ittner, Y. D. Ke, F. Delerue, M. Bi, A. Gladbach, J. van
Eersel, H. Wolfing, B. C. Chieng, M. J. Christie, I. A. Napier,
A. Eckert, M. Staufenbiel, E. Hardeman and J. Gotz, Cell,
2010, 142, 387.
10 F. X. Soriano, M. A. Martel, S. Papadia, A. Vaslin, P. Baxter,
C. Rickman, J. Forder, M. Tymianski, R. Duncan, M. Aarts,
P. Clarke, D. J. Wyllie and G. E. Hardingham, J. Neurosci.,
2008, 28, 10696.
11 M. D. Hill, R. H. Martin, D. Mikulis, J. H. Wong, F. L. Silver,
K. G. Terbrugge, G. Milot, W. M. Clark, R. L. Macdonald,
M. E. Kelly, M. Boulton, I. Fleetwood, C. McDougall, T.
Gunnarsson, M. Chow, C. Lum, R. Dodd, J. Poublanc, T.
Krings, A. M. Demchuk, M. Goyal, R. Anderson, J. Bishop, D.
Garman, M. Tymianski and ENACT trial investigators, Lancet
Neurol., 2012, 11, 942.
12 J. Schultz, R. R. Copley, T. Doerks, C. P. Ponting and P.
Bork, Nucleic Acids Res., 2000, 28, 231.
13 C. N. Chi, A. Bach, K. Strømgaard, S. Gianni and P. Jemth,
BioFactors, 2012, 38, 338.
14 D. A. Doyle, A. Lee, J. Lewis, E. Kim, M. Sheng and R.
MacKinnon, Cell, 1996, 85, 1067.
15 A. Bach, C. N. Chi, T. B. Olsen, S. W. Pedersen, M. U. Røder,
G. F. Pang, R. P. Clausen, P. Jemth and K. Strømgaard,
J. Med. Chem., 2008, 51, 6450.
16 M. A. Stiffler, J. R. Chen, V. P. Grantcharova, Y. Lei, D.
Fuchs, J. E. Allen, L. A. Zaslavskaia and G. MacBeath,
Science, 2007, 317, 364.
17 B. Z. Harris, F. W. Lau, N. Fujii, R. K. Guy and W. A. Lim,
Biochemistry, 2003, 42, 2797.
18 S. W. Pedersen, S. B. Pedersen, L. Anker, G. Hultqvist, A. S.
Kristensen, P. Jemth and K. Strømgaard, Nat. Commun.,
2014, 5, 3215.
19 J. N. Eildal, G. Hultqvist, T. Balle, N. Stuhr-Hansen, S.
Padrah, S. Gianni, K. Strømgaard and P. Jemth, J. Am. Chem.
Soc., 2013, 135, 12998.
20 A. Bach, J. N. Eildal, N. Stuhr-Hansen, R. Deeskamp, M.
Gottschalk, S. W. Pedersen, A. S. Kristensen and K.
Strømgaard, J. Med. Chem., 2011, 54, 1333.
21 A. Bach, C. N. Chi, G. F. Pang, L. Olsen, A. S. Kristensen, P.
Jemth and K. Strømgaard, Angew. Chem., Int. Ed., 2009, 48,
9685.
22 A. Piserchio, G. D. Salinas, T. Li, J. Marshall, M. R. Spaller
and D. F. Mierke, Chem. Biol., 2004, 11, 469.
23 D. G. Udugamasooriya, S. C. Sharma and M. R. Spaller,
ChemBioChem, 2008, 9, 1587.
24 A. Vogrig, L. Dorr, N. Bouzidi, B. Boucherle, A. S. Wattiez, E.
Cassier, G. Vallon, I. Ripoche, I. Abrunhosa-Thomas, P.
Marin, L. Nauton, V. Thery, C. Courteix, L. Y. Lian and S.
Ducki, ACS Chem. Biol., 2013, 8, 2209.
25 C. W. Tornøe, C. Christensen and M. Meldal, J. Org. Chem.,
2002, 67, 3057.
26 V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B.
Sharpless, Angew. Chem., Int. Ed., 2002, 41, 2596.
27 Y. L. Angell and K. Burgess, Chem. Soc. Rev., 2007, 36, 1674.
28 A. Trabocchi and A. Guarna, in Peptidomimetics in Organic
and Medicinal Chemistry, John Wiley & Sons, Ltd, 2014, ch. 5,
pp. 99–121.
29 A. Brik, J. Alexandratos, Y. C. Lin, J. H. Elder, A. J. Olson, A.
Wlodawer, D. S. Goodsell and C. H. Wong, ChemBioChem,
2005, 6, 1167.
30 I. E. Valverde, A. Bauman, C. A. Kluba, S. Vomstein, M. A.
Walter and T. L. Mindt, Angew. Chem., Int. Ed., 2013, 52,
8957.
31 J. T. Lundquist and J. C. Pelletier, Org. Lett., 2001, 3, 781.
32 H. Johansson and D. S. Pedersen, Eur. J. Org. Chem.,
2012, 4267.
33 A. Bach and K. Strømgaard, Synthesis, 2011, 807.
34 N. B. Kondekar and P. Kumar, Synth. Commun., 2011, 41,
1301.
35 S. Mosca, F. Wojcik and L. Hartmann, Macromol. Rapid
Commun., 2011, 32, 197.
36 G. J. Roth, B. Leipold, S. G. Müller and H. J. Bestmann,
Synthesis, 2004, 640.
37 G. Reginato, A. Mordini, F. Messina, A. Degl'Innocenti and
G. Poli, Tetrahedron, 1996, 52, 10985.
38 P. K. Chakravarty, W. J. Greenlee, W. H. Parsons, A. A.
Patchett, P. Combs, A. Roth, R. D. Busch and T. N. Mellin,
J. Med. Chem., 1989, 32, 1886.
39 N. Umezawa, N. Matsumoto, S. Iwama, N. Kato and T.
Higuchi, Bioorg. Med. Chem., 2010, 18, 6340.
40 T. Wiseman, S. Williston, J. F. Brandts and L. N. Lin, Anal.
Biochem., 1989, 179, 131.
41 W. B. Turnbull and A. H. Daranas, J. Am. Chem. Soc.,
2003, 125, 14859.
MedChemCommResearch Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
8 
Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
on
 0
5/
01
/2
01
8 
11
:4
6:
19
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
